News
Moon Shots Program
Since starting the Moon Shots Program® in 2012, we’ve made progress. And lots of it. Keep checking back here to stay up-to-date on the program’s achievements and see our latest innovations.
/cancermoonshots/about/news.html
According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed.
The trial results were...
The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation today announced a three-year strategic research collaboration...
The University of Texas MD Anderson Cancer Center and Hummingbird Bioscience today announced the launch of a multi-year strategic research...
Preclinical research from The University of Texas MD Anderson Cancer Center finds that although glioblastoma stem cells (GSCs) can be targeted...
A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic...